Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.

Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, Barnard D, Bouchard A, Jaski B, Lyon AR, Pogoda JM, Rudy JJ, Zsebo KM.

Lancet. 2016 Mar 19;387(10024):1178-86. doi: 10.1016/S0140-6736(16)00082-9. Epub 2016 Jan 21.

2.

Small Molecular Allosteric Activator of the Sarco/Endoplasmic Reticulum Ca2+-ATPase (SERCA) Attenuates Diabetes and Metabolic Disorders.

Kang S, Dahl R, Hsieh W, Shin A, Zsebo KM, Buettner C, Hajjar RJ, Lebeche D.

J Biol Chem. 2016 Mar 4;291(10):5185-98. doi: 10.1074/jbc.M115.705012. Epub 2015 Dec 23.

3.

Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure.

Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Pogoda JM, Provost R, Guerrero J, Hajjar RJ, Zsebo KM.

Gene Ther. 2016 Mar;23(3):313-9. doi: 10.1038/gt.2015.109. Epub 2015 Dec 24.

4.

Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b).

Greenberg B, Yaroshinsky A, Zsebo KM, Butler J, Felker GM, Voors AA, Rudy JJ, Wagner K, Hajjar RJ.

JACC Heart Fail. 2014 Feb;2(1):84-92. doi: 10.1016/j.jchf.2013.09.008. Epub 2014 Jan 25.

5.

Discovery of enzyme modulators via high-throughput time-resolved FRET in living cells.

Gruber SJ, Cornea RL, Li J, Peterson KC, Schaaf TM, Gillispie GD, Dahl R, Zsebo KM, Robia SL, Thomas DD.

J Biomol Screen. 2014 Feb;19(2):215-22. doi: 10.1177/1087057113510740.

6.

Stem cell factor gene transfer promotes cardiac repair after myocardial infarction via in situ recruitment and expansion of c-kit+ cells.

Yaniz-Galende E, Chen J, Chemaly E, Liang L, Hulot JS, McCollum L, Arias T, Fuster V, Zsebo KM, Hajjar RJ.

Circ Res. 2012 Nov 9;111(11):1434-45. doi: 10.1161/CIRCRESAHA.111.263830. Epub 2012 Aug 29.

7.

High-throughput FRET assay yields allosteric SERCA activators.

Cornea RL, Gruber SJ, Lockamy EL, Muretta JM, Jin D, Chen J, Dahl R, Bartfai T, Zsebo KM, Gillispie GD, Thomas DD.

J Biomol Screen. 2013 Jan;18(1):97-107. doi: 10.1177/1087057112456878. Epub 2012 Aug 24.

8.

Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.

Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ; Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators.

Circulation. 2011 Jul 19;124(3):304-13. doi: 10.1161/CIRCULATIONAHA.111.022889. Epub 2011 Jun 27.

9.

Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B, Borow K, Dittrich H, Zsebo KM, Hajjar RJ; Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators.

J Card Fail. 2009 Apr;15(3):171-81. doi: 10.1016/j.cardfail.2009.01.013.

10.

Measurement of human and murine stem cell factor (c-kit ligand).

Smith KA, Zsebo KM.

Curr Protoc Immunol. 2001 May;Chapter 6:Unit 6.17. doi: 10.1002/0471142735.im0617s04.

PMID:
18432808
11.

Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains.

Roberts MR, Cooke KS, Tran AC, Smith KA, Lin WY, Wang M, Dull TJ, Farson D, Zsebo KM, Finer MH.

J Immunol. 1998 Jul 1;161(1):375-84.

12.

Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice.

Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, Gallo ML, Louie DM, Lee DV, Erickson KL, Luna J, Roy CM, Abderrahim H, Kirschenbaum F, Noguchi M, Smith DH, Fukushima A, Hales JF, Klapholz S, Finer MH, Davis CG, Zsebo KM, Jakobovits A.

Nat Genet. 1997 Feb;15(2):146-56. Erratum in: Nat Genet 1997 Aug;16(4):410.

PMID:
9020839
13.
14.

Human thymocyte responsiveness to stem cell factor: synergy with interleukin-2 for the generation of NK/LAK cytotoxicity.

Uittenbogaart CH, Schmidc I, Kiertscher S, Shau H, Anisman DJ, Zsebo KM, Clement LT.

Immunol Lett. 1996 Aug;52(1):45-52.

PMID:
8877418
15.

Long-term treatment of canine cyclic hematopoiesis with recombinant canine stem cell factor.

Dale DC, Rodger E, Cebon J, Ramesh N, Hammond WP, Zsebo KM.

Blood. 1995 Jan 1;85(1):74-9.

16.

Cell surface expression of c-kit receptors by childhood acute myeloid leukemia blasts is not of prognostic value: a report from the Childrens Cancer Group.

Smith FO, Broudy VC, Zsebo KM, Lampkin BC, Buckley CV, Buckley JD, Opie T, Woods WG, Hammond GD, Bernstein ID.

Blood. 1994 Aug 1;84(3):847-52.

17.
18.

[Effects of recombinant stem cell factor on the proliferation in vitro of LT12 acute promyelocytic leukemic cell line].

Xi YZ, Martens AC, Zsebo KM.

Zhonghua Zhong Liu Za Zhi. 1994 Mar;16(2):93-7. Chinese.

PMID:
7523053
19.

Characterization of cultured mast cells derived from Ws/Ws mast cell-deficient rats with a small deletion at tyrosine kinase domain of c-kit.

Tei H, Kasugai T, Tsujimura T, Adachi S, Furitsu T, Tohya K, Kimura M, Zsebo KM, Newlands GF, Miller HR, et al.

Blood. 1994 Feb 15;83(4):916-25.

20.

In vitro effects of stem-cell factor or interleukin-3 on myelosuppression associated with AIDS.

Scadden DT, Wang A, Zsebo KM, Groopman JE.

AIDS. 1994 Feb;8(2):193-6.

PMID:
7519020
21.

The kit ligand, stem cell factor.

Galli SJ, Zsebo KM, Geissler EN.

Adv Immunol. 1994;55:1-96. Review. No abstract available.

PMID:
7508174
22.

The in vivo effects of steel factor on natural killer lineage cells in murine spleen and bone marrow.

Miller SC, Fleming WH, Zsebo KM, Weissman IL.

Nat Immun. 1993 Nov-Dec;12(6):293-301.

PMID:
7505667
23.
24.
25.

Phenotypic characterization of stem cell factor-dependent human foetal liver-derived mast cells.

Nilsson G, Forsberg K, Bodger MP, Ashman LK, Zsebo KM, Ishizaka T, Irani AM, Schwartz LB.

Immunology. 1993 Jun;79(2):325-30.

26.

Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene.

Sekido Y, Takahashi T, Ueda R, Takahashi M, Suzuki H, Nishida K, Tsukamoto T, Hida T, Shimokata K, Zsebo KM, et al.

Cancer Res. 1993 Apr 1;53(7):1709-14.

27.

Soluble stem cell factor in human serum.

Langley KE, Bennett LG, Wypych J, Yancik SA, Liu XD, Westcott KR, Chang DG, Smith KA, Zsebo KM.

Blood. 1993 Feb 1;81(3):656-60.

28.

Human stem cell factor (c-kit ligand) induces an autocrine loop of growth in a GM-CSF-dependent megakaryocytic leukemia cell line.

Kiss C, Cesano A, Zsebö KM, Clark SC, Santoli D.

Leukemia. 1993 Feb;7(2):235-40.

PMID:
7678880
29.

Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand.

Mitsui H, Furitsu T, Dvorak AM, Irani AM, Schwartz LB, Inagaki N, Takei M, Ishizaka K, Zsebo KM, Gillis S, et al.

Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):735-9.

30.

Regulation of mouse peritoneal mast cell secretory function by stem cell factor, IL-3 or IL-4.

Coleman JW, Holliday MR, Kimber I, Zsebo KM, Galli SJ.

J Immunol. 1993 Jan 15;150(2):556-62.

PMID:
7678275
31.

The role of stem cell factor in the hematopoietic system.

McNiece IK, Zsebo KM.

Cancer Invest. 1993;11(6):724-9. Review. No abstract available.

PMID:
7693311
32.

Hematologic effects of stem cell factor alone and in combination with G-CSF and GM-CSF in vivo and in vitro in rodents.

Ulich TR, Yi ES, Yin S, del Castillo J, McNiece I, Yung YP, Zsebo KM.

Int Rev Exp Pathol. 1993;34 Pt A:215-33.

PMID:
7681048
33.

Reversible expansion of primate mast cell populations in vivo by stem cell factor.

Galli SJ, Iemura A, Garlick DS, Gamba-Vitalo C, Zsebo KM, Andrews RG.

J Clin Invest. 1993 Jan;91(1):148-52.

34.
35.
36.

Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells.

Irani AM, Nilsson G, Miettinen U, Craig SS, Ashman LK, Ishizaka T, Zsebo KM, Schwartz LB.

Blood. 1992 Dec 15;80(12):3009-21.

37.

The production of steel factor mRNA in Diamond-Blackfan anaemia long-term cultures and interactions of steel factor with erythropoietin and interleukin-3.

Sieff CA, Yokoyama CT, Zsebo KM, Trammell J, Andersen JW, Nathan DG, Williams DA.

Br J Haematol. 1992 Dec;82(4):640-7.

PMID:
1282827
38.

The ligand for c-kit, stem cell factor, stimulates the circulation of cells that engraft lethally irradiated baboons.

Andrews RG, Bensinger WI, Knitter GH, Bartelmez SH, Longin K, Bernstein ID, Appelbaum FR, Zsebo KM.

Blood. 1992 Dec 1;80(11):2715-20.

39.

Isolation of rat bone marrow mast lineage cells using Thy 1.1 and rat stem cell factor.

Medlock ES, Mineo C, Housman JM, Elliott GS, Trebasky LD, Langley KE, Zsebo KM.

J Cell Physiol. 1992 Dec;153(3):498-506.

PMID:
1280277
40.

Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture.

Valent P, Spanblöchl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, Strobl H, Geissler K, Bettelheim P, Lechner K.

Blood. 1992 Nov 1;80(9):2237-45.

41.

Effects of stem cell factor on osteoclast-like cell formation in long-term human marrow cultures.

Demulder A, Suggs SV, Zsebo KM, Scarcez T, Roodman GD.

J Bone Miner Res. 1992 Nov;7(11):1337-44.

PMID:
1281606
42.

Radioprotection of mice by recombinant rat stem cell factor.

Zsebo KM, Smith KA, Hartley CA, Greenblatt M, Cooke K, Rich W, McNiece IK.

Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9464-8.

43.

Interaction of human bone marrow fibroblasts with megakaryocytes: role of the c-kit ligand.

Avraham H, Scadden DT, Chi S, Broudy VC, Zsebo KM, Groopman JE.

Blood. 1992 Oct 1;80(7):1679-84.

44.
45.

A c-kit ligand, recombinant human stem cell factor, mediates reversible expansion of multiple CD34+ colony-forming cell types in blood and marrow of baboons.

Andrews RG, Bartelmez SH, Knitter GH, Myerson D, Bernstein ID, Appelbaum FR, Zsebo KM.

Blood. 1992 Aug 15;80(4):920-7.

46.

Evidence that stem cell factor is involved in the rebound thrombocytosis that follows 5-fluorouracil treatment.

Hunt P, Zsebo KM, Hokom MM, Hornkohl A, Birkett NC, del Castillo JC, Martin F.

Blood. 1992 Aug 15;80(4):904-11.

47.

The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils.

Columbo M, Horowitz EM, Botana LM, MacGlashan DW Jr, Bochner BS, Gillis S, Zsebo KM, Galli SJ, Lichtenstein LM.

J Immunol. 1992 Jul 15;149(2):599-608.

PMID:
1378071
48.

Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors.

Turner AM, Zsebo KM, Martin F, Jacobsen FW, Bennett LG, Broudy VC.

Blood. 1992 Jul 15;80(2):374-81.

49.

Human recombinant stem cell factor stimulates in vitro proliferation of acute myeloid leukemia cells and expands the clonogenic cell pool.

Carlesso N, Pregno P, Bresso P, Gallo E, Pileri A, Zsebo KM, Ferrero D.

Leukemia. 1992 Jul;6(7):642-8.

PMID:
1378162
50.

Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor.

Broudy VC, Smith FO, Lin N, Zsebo KM, Egrie J, Bernstein ID.

Blood. 1992 Jul 1;80(1):60-7.

Supplemental Content

Loading ...
Support Center